GlassScriptPhysician profile
William W Ting
NPI 1235105446
$4,270.02
in general payments reported to CMS, 2019-2025
25 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $13.62 · 2021: $40.78 · 2023: $358 · 2024: $1,047 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,629 · Education: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,628.58 |
| Education | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $546.76 | 2021-2025 | Skyrizi |
| Regeneron Pharmaceuticals, INC. | $526.08 | 2019 | |
| Ucb, INC. | $265.95 | 2024-2025 | Bimzelx |
| Incyte Corporation | $262.95 | 2023-2025 | Opzelura |
| Genzyme Corporation | $258.43 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $257.55 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $233.70 | 2024-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $211.04 | 2023-2025 | Dupixent, Libtayo |
| Pfizer INC. | $189.92 | 2023-2025 | |
| Almirall LLC | $188.74 | 2024-2025 | Klisyri |
| Janssen Biotech, INC. | $185.81 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Merz North America, INC. | $165.63 | 2019-2023 | Xeomin |
| Organon LLC | $151.09 | 2025 | Nexplanon, Vtama |
| Galderma Laboratories, L.P. | $142.43 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $128.12 | 2024-2025 | Jublia, Siliq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $119.95 | 2024-2025 | |
| Leo Pharma INC. | $70.82 | 2024-2025 | Adbry |
| Amgen INC. | $65.59 | 2024-2025 | Otezla, Otezla |
| Botanix Sb INC | $60.23 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $60.15 | 2025 | |
| Genentech USA, INC. | $50.90 | 2023-2025 | Xolair |
| Janssen Scientific Affairs, LLC | $43.23 | 2024 | Tremfya |
| Dermavant Sciences, INC. | $42.35 | 2024 | Vtama |
| Cipher Pharmaceuticals US LLC | $28.98 | 2025 | Natroba, Spinosad |
| Allergan, INC. | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.